ABBOTT INDIA LTD
Abbott Announces Collaborations, Reinforces its Commitment Towards Access to Holistic Diabetes Care
Mumbai, February 9 2022: Abbott, the global healthcare leader, announced new collaborations with key health-tech partners BeatO, Sugar.fit, PharmEasy, GOQii, 1MG, Zyla Health, Healthifyme and Fitterfly to usher a new era of holistic diabetes management care. Through these collaborations, Abbott aims to offer glucose monitoring solutions to 8 million people living with diabetes, of which approximately 6.5mn users can access through PharmEasy and 1MG. The company is focused on maintaining effective glucose level along with remote consultations, diabetes-specific coaching, and dietary plans.
India has the second-highest diabetes population in the world1. Recent studies show that healthcare for non-communicable diseases has been interrupted in India, with up to 87% of people with diabetes reducing visits to their doctor due to the pandemic, and less than half possessing a blood glucose measuring device at home.2. For adults with type 2 diabetes on intensive insulin, studies showed average HbA1c drop from 8.9% to 8% with at least three months of using sensor-based devices, which continuously monitored glucose.1 Through these collaborations, Abbott endeavors to enable personalized lifestyle and therapy interventions, so people with diabetes can achieve holistic glucose management goals.
The pandemic led to the deployment of disruptive technologies in the healthcare industry leading to breakthroughs in patient care. For example, sensor-based monitoring devices and virtual consultations are helping people manage glucose levels at home. Availability of wearable devices such as Abbott’s FreeStyle Libre have enabled patients to continuously monitor glucose levels and provide real time insights to doctors. Abbott has also partnered with BeatO, a digital health platform to launch a holistic, data-based continuous glucose monitoring program for better diabetes management. The program provides users access to targeted diet, help in controlling diabetes and lifestyle counselling from experts based on the data recorded by FreeStyle Libre.
Kalyan Sattaru, General Manager of the diabetes care business at Abbott, said, “Continued research and strategic partnerships have simplified and strengthened diabetes management over the years. New diabetes technology has paved the way for precise and informed decision making. Connecting our partner brands’ products with the FreeStyle Libre portfolio will enable users to capture their glucose data easily as part of an integrated system.”
Gautam Chopra, Co-founder & CEO, BeatO commented, “Leveraging Abbott’s FreeStyle Libre with BeatO’s app ecosystem will give our users precise data, along with actionable insights to effectively manage and control blood glucose levels. We are continuously striving to make diabetes management more effective and convenient for our members and this program is a step in the same direction.”
Addition of Abbott’s FreeStyle Libre to BeatO’s current offerings prompts diabetes educators and nutritionists to provide more patient-specific and targeted diet counselling to users. For members who had uncontrolled diabetes, this has resulted in 90% of them now having their blood glucose levels within a time in range of more than 75%.
Madan Somasundaram, Co-founder and CEO, Sugar.fit said, "At Sugar.fit, our mission is to empower people with chronic conditions to live better and healthier lives and reverse chronic metabolic disorders. Technology is combined with science and human coaching to help millions of Indians manage and reverse diabetes through a highly consumer-centric data-driven digital health experience."
Sugar.fit’s program, launched in June 2021, has helped 90%+ of its users see drastic improvement in sugar levels with most users seeing an average drop of 1.9% in HbA1c levels, just within 3 months. This was in addition to sustained weight loss and significant reduction in medicines for patients with more than 8% HbA1c levels.
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.
Smritee Chaturvedi | 8291501096 | firstname.lastname@example.org
Spanakis EG, Chiarugi F, Kouroubali A, et al. Diabetes management using modern information and communication technologies and new care models. Interact J Med Res. 2012;1(2):e8. Published 2012 Oct 4. doi:10.2196/ijmr.2193
2 A cross sectional study reveals severe disruption in glycemic control in people with diabetes during and after lockdown in India. Mohammed Abdul Khadera, Talha Jabeena, Ramanachary Namojuab. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, Volume 14, Issue 6, November–December 2020, Pages 1579-1584 - https://doi.org/10.1016/j.dsx.2020.08.011
3 Bajaj, Sarita, RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017, International Journal of Diabetes in Developing Countries (March 2018) 38 (Suppl 1):S1–S115 https://doi.org/10.1007/s13410-018-0604-7
4 Haak, Thomas, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Therapy 8.1 (2017): 55-73r. - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306122/
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.